Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer
This book-entitled "Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer"-was edited as a Special Issue of Biomedicines, focusing on basic research such as genomics, epigenomics, and proteomics, as well as clinical research in the field of gynecologic oncology. The number of...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_87502 | ||
| 005 | 20220706 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220706s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4384-0 | ||
| 020 | |a 9783036543833 | ||
| 020 | |a 9783036543840 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4384-0 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MBN |2 bicssc | |
| 100 | 1 | |a Nakayama, Naomi |4 edt | |
| 700 | 1 | |a Nakayama, Naomi |4 oth | |
| 245 | 1 | 0 | |a Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (258 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This book-entitled "Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer"-was edited as a Special Issue of Biomedicines, focusing on basic research such as genomics, epigenomics, and proteomics, as well as clinical research in the field of gynecologic oncology. The number of patients with gynecological cancer has been increasing worldwide due to its high lethality and lack of early detection tools and effective therapeutic interventions. In this regard, basic research on its pathophysiology and novel molecular targeting intervention is required to improve the prognosis of gynecologic cancer. This book contains 13 papers, including 8 original research papers and 5 reviews focusing on the basic research of gynecologic oncology. The reader can learn about state-of-the-art research and obtain extensive knowledge of the current advances in the field of gynecologic oncology. It is my hope that this book contributes towards the progress of gynecologic oncology. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Public health & preventive medicine |2 bicssc | |
| 653 | |a nucleus accumbens-associated protein 1 (NAC1) | ||
| 653 | |a BEN (BANP, E5R and NAC1) domain | ||
| 653 | |a sequence-specific DNA-binding protein | ||
| 653 | |a solution NMR structure | ||
| 653 | |a isothermal titration calorimetry (ITC) | ||
| 653 | |a human cytomegalovirus | ||
| 653 | |a ovarian cancer | ||
| 653 | |a cancer progression | ||
| 653 | |a inflammation | ||
| 653 | |a immunosuppression | ||
| 653 | |a endometrial carcinoma | ||
| 653 | |a immune micro-environment | ||
| 653 | |a immune checkpoints inhibitors | ||
| 653 | |a microsatellite instability | ||
| 653 | |a mismatch repair deficiency | ||
| 653 | |a platelet-activating factor acetylhydrolase (PAF-AH | ||
| 653 | |a PLA2G7) | ||
| 653 | |a BRCA1 mutant ovarian cancer | ||
| 653 | |a Wnt signaling | ||
| 653 | |a pGSK3β | ||
| 653 | |a β-catenin | ||
| 653 | |a prognosis | ||
| 653 | |a vulvar melanoma | ||
| 653 | |a vaginal melanoma | ||
| 653 | |a targeted therapy | ||
| 653 | |a gynecological cancer | ||
| 653 | |a melanoma treatment | ||
| 653 | |a gene ontology | ||
| 653 | |a epithelial ovarian cancers | ||
| 653 | |a borderline ovarian tumors | ||
| 653 | |a differentially expressed genes | ||
| 653 | |a aryl hydrocarbon receptor | ||
| 653 | |a epithelial-mesenchymal transition | ||
| 653 | |a integrative analysis | ||
| 653 | |a testin | ||
| 653 | |a p16 protein | ||
| 653 | |a cervical cancer | ||
| 653 | |a cervical neoplasia | ||
| 653 | |a immunohistochemistry | ||
| 653 | |a chimeric antigen receptor | ||
| 653 | |a CD44 | ||
| 653 | |a adoptive immunotherapy | ||
| 653 | |a NK cells | ||
| 653 | |a epithelial ovarian cancer | ||
| 653 | |a DNA damage response | ||
| 653 | |a somatic mutation | ||
| 653 | |a clear cell carcinoma | ||
| 653 | |a endometrioid endometrial cancer | ||
| 653 | |a DNA mismatch repair (MMR) | ||
| 653 | |a MMR deficient (dMMR) | ||
| 653 | |a long-term survival | ||
| 653 | |a exosome | ||
| 653 | |a miRNA | ||
| 653 | |a biomarkers | ||
| 653 | |a liquid biopsy | ||
| 653 | |a interventional radiotherapy | ||
| 653 | |a vaginal-cuff brachytherapy | ||
| 653 | |a HDR brachytherapy | ||
| 653 | |a in vivo dosimetry | ||
| 653 | |a endometrial cancer | ||
| 653 | |a biological planning | ||
| 653 | |a drug repurposing | ||
| 653 | |a non-coding RNAs | ||
| 653 | |a nanocarriers | ||
| 653 | |a anti-angiogenic therapy | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5700 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/87502 |7 0 |z DOAB: description of the publication |